Cargando…

RNA editing derived epitopes function as cancer antigens to elicit immune responses

In addition to genomic mutations, RNA editing is another major mechanism creating sequence variations in proteins by introducing nucleotide changes in mRNA sequences. Deregulated RNA editing contributes to different types of human diseases, including cancers. Here we report that peptides generated a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Minying, Fritsche, Jens, Roszik, Jason, Williams, Leila J., Peng, Xinxin, Chiu, Yulun, Tsou, Chih-Chiang, Hoffgaard, Franziska, Goldfinger, Valentina, Schoor, Oliver, Talukder, Amjad, Forget, Marie A., Haymaker, Cara, Bernatchez, Chantale, Han, Leng, Tsang, Yiu-Huen, Kong, Kathleen, Xu, Xiaoyan, Scott, Kenneth L., Singh-Jasuja, Harpreet, Lizee, Greg, Liang, Han, Weinschenk, Toni, Mills, Gordon B., Hwu, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156571/ https://www.ncbi.nlm.nih.gov/pubmed/30254248 http://dx.doi.org/10.1038/s41467-018-06405-9

Ejemplares similares

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand
por: Fritsche, Jens, et al.
Publicado: (2021)

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity
por: Forget, Marie-Andrée, et al.
Publicado: (2015)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
por: Haymaker, Cara L, et al.
Publicado: (2015)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
por: Li, Fenge, et al.
Publicado: (2021)

Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection
por: Fritsche, Jens, et al.
Publicado: (2018)

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
por: Walter, Steffen, et al.
Publicado: (2013)

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
por: Parra, Edwin R., et al.
Publicado: (2017)

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
por: Fix, Samantha M, et al.
Publicado: (2022)

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
por: Im, Jin S., et al.
Publicado: (2016)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy
por: Forget, Marie-Andrée, et al.
Publicado: (2013)

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue
por: Parra, Edwin Roger, et al.
Publicado: (2021)

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
por: Bradley, Sherille D., et al.
Publicado: (2020)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Forging a link between oncogenic signaling and immunosuppression in melanoma
por: Khalili, Jahan S., et al.
Publicado: (2013)

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
por: Punt, Simone, et al.
Publicado: (2020)

Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015)

Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
por: Sun, Yimo, et al.
Publicado: (2021)

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators
por: Qin, Yong, et al.
Publicado: (2017)

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
por: Roszik, Jason, et al.
Publicado: (2016)

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
por: Mbofung, Rina M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l6bpqosdbnh3n0avo7j6dm2qjp